Back to Authors

Pulini, Jennifer

A5001287707 | I924451375

Mayo Clinic

Incyte (United States)

Citations 4

Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8520-8520

10.1200/jco.2015.33.15_suppl.8520

A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8558-8558

10.1200/jco.2015.33.15_suppl.8558

A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8607-TPS8607

10.1200/jco.2015.33.15_suppl.tps8607

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Blood | April 25, 2018 | Volume: 132 | Issue: 3 | Pages: 293-306

10.1182/blood-2017-10-812701 | PMID 29695516

Key PointsINCB040093 was active across lymphoma subtypes, and the addition of itacitinib provided substantial activity in classic Hodgkin lymphoma. INCB040093 ± itacitinib had a manageable safety and tolerability profile; severe hepatic adverse effects were less common with the combination.